Interferon alpha-2b/interferon gamma - Heber Biotech

Drug Profile

Interferon alpha-2b/interferon gamma - Heber Biotech

Alternative Names: CIGB-128; CIGB-128-A; HeberFERON; HeberPAG; Interferon-alpha-2b/interferon-gamma; Interferon-gamma/interferon-alpha-2b

Latest Information Update: 18 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Class Antineoplastics; Antivirals; Interferons; Lymphokines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Basal cell cancer
  • Phase I Mycosis fungoides
  • Preclinical Brain cancer

Most Recent Events

  • 09 Jan 2017 Center for Genetic Engineering and Biotechnology plans a phase I/II trial in Renal cell carcinoma in Cuba (RPCEC00000229)
  • 04 Feb 2016 This programme is still active
  • 04 Feb 2016 Interferon alpha-2b/interferon gamma - Heber Biotech is available for licensing. http://gndp.cigb.edu.cu
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top